SLC39A4 and pancreatic adenocarcinoma: Notably, the genetic alteration rate of SLC39A1 in LIHC reached 11%, while the rates of SLC39A4 in CESC and PAAD were 3% and 10%, respectively, primarily characterized by amplification.